- Medicine Access and Rational Use > Pricing
- Public Health, Innovation, Intellectual Property and Trade > Intellectual Property (IP) and Trade
- Palabras clave > globalization
- Palabras clave > patentability criteria - policy options
- Palabras clave > pharmaceutical consumption
- Palabras clave > prices / pricing policy
- Palabras clave > Trade Related Aspects of the Intellectual Property Rights (TRIPS)
- Palabras clave > TRIPS flexibilities
- Palabras clave > TRIPS-plus provisions
(2002; 67 pages)
Network for Monitoring the Impact of Globalization and TRIPS on Access to Medicines, Meeting Report, 19-21 February 2001, Chulalongkorn University, Bangkok, Thailand - Health Economics and Drugs Series No. 011
Note to the reader
The harmonized model of selected indicators included in this document represents an historical snapshot of the network’s endeavours to fulfil the mandate of the World Health Assembly in resolution WHA52.19 on the Revised Drug Strategy. It should be noted that these indicators are a work in progress. As such, the network is aware that the template does not yet contain indicators to monitor the impact of expanded intellectual property protections on the development of drugs for neglected diseases. Initial field tests by the Collaborating Centres should help identify any major problems with the indicator template: data that is not accessible, unclear or problematic methodologies for data collection, unclear definitions. After initial field testing, the network’s steering committee will review and revise the template as appropriate. After this initial revision, it will be important for the basic indicators to remain constant to ensure data consistency across time; but the steering committee will work to continuously clarify and revise the template based on accumulated experience. In addition, the WHO Collaborating Centre for Health Economics and Drug Policies in London is currently writing a manual for using the template.
This document is not a policy paper but a draft framework to collect data for further analysis. Comments are welcome.
© World Health Organization 2002
This document is not a formal publication of the World Health Organization (WHO), and all rights are reserved by the Organization. The document may, however, be freely reviewed, abstracted, reproduced and translated, in part or in whole, but not for sale nor for use in conjunction with commercial purposes.
The views expressed in this document by named authors are solely the responsibility of these authors.
This report consists of a collection of documents including a brief introduction, opening remarks, WHO perspectives on globalization and access to pharmaceuticals, a template of selected model indicators, and plans of actions from participating WHO Collaborating Centres.